BioCentury | Jan 6, 2017
Company News

Vectura, Mundipharma deal

...U.S. company exercised an option from Vectura to license exclusive, worldwide rights to VR2076 (formerly SKP-2076...
...regulatory and product launch milestones, plus royalties starting around the mid-single-digits. Mundipharma may also develop VR2076...
...Ltd. , Cambridge, U.K. Business: Inflammation, Pulmonary Alex Himes SKP-2076 Mundipharma International Ltd. Vectura Group plc Adrenergic receptor beta 2 Muscarinic receptor VR2076...
BioCentury | Jan 11, 2016
Company News

Skyepharma, Mundipharma deal

...Skyepharma granted Mundipharma an option to license exclusive, worldwide rights to develop and commercialize SKP-2076 following...
...declined to disclose which indications would be pursued with SKP-2076, but Skyepharma previously had said SKP-2076...
...exercised, is eligible to receive milestones, plus royalties. The partners declined to disclose financial terms. SKP-2076...
Items per page:
1 - 2 of 2